Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: As antigenic stimulation of the B cell antigen receptor (BCR) is key to chronic lymphocytic leukaemia (CLL) pathogenesis, targeting dysregulated kinases involved in BCR signalling is an attractive therapeutic approach. We studied the effects of the Src/c‐Abl tyrosine kinase inhibitor dasatinib on BCR signal transduction in CLL cells. Treatment of CLL cells with 100 nmol/l dasatinib induced apoptosis by an average reduction in viability of 33·7% at 48 h, with dasatinib sensitivity correlating with inhibition of Syk Y348 phosphorylation. Dasatinib inhibited calcium flux, phosphatidylinositol‐3‐kinase and mitogen‐activated protein kinase activation following BCR crosslinking, and blocked the Mcl‐1‐dependent increase in CLL cell survival on prolonged BCR stimulation. However, the pro‐apoptotic effect of dasatinib was abrogated by stromal cell contact alone or in the presence of CD154 and interleukin (IL)‐4 (CD154L/IL‐4 system). Whilst dasatinib retained the ability to sensitize CLL cells in stromal co‐culture to both fludarabine and chlorambucil, the addition of CD154 and IL‐4 rendered cells resistant to these drug combinations. We demonstrate that the HSP90 inhibitor 17‐DMAG exhibited synergy with dasatinib in vitro, and moreover, induced apoptosis of CLL cells in the CD154L/IL‐4 system. Our data provide evidence that dasatinib would be most clinically effective in combination with agents able to target antigen‐independent microenvironmental signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Gobessi, S., Laurenti, L., Longo, P. G., Carsetti, L., Berno, V, Sica, S., Leone, G., & Efremov, D. G. (2009) · Leukemia · doi:10.1038/leu.2008.346 · Cited by 200
Yang, C., Lu, P., Lee, F. Y., Chadburn, A., Barrientos, J. C., Leonard, J. P., Ye, F., Zhang, D., Knowles, D. M., & Wang, Y. L. (2008) · Leukemia · doi:10.1038/leu.2008.163 · Cited by 61 · cited 4×
“Of note, recent studies in DLBCL cell lines have also shown dasatinib sensitivity to correlate with the inhibition of BCR signal transduction (Yang et al, 2008; Hollmann et al, 2010).”
BackgroundMethodInfluentialSong, Z., Lu, P., Furman, R. R., Leonard, J. P., Martin, P., Tyrell, L., Lee, F. Y., Knowles, D. M., Coleman, M., & Wang, Y. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1519 · Cited by 59 · cited 3×
“Song et al (2010) concluded that Syk inhibitors may have more therapeutic potential than dasatinib in CLL.”
BackgroundResult
Cited by
B-cell receptor signaling in chronic lymphocytic leukemia
Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J., & Packham, G. (2011) · Blood · doi:10.1182/blood-2011-06-338855 · Cited by 390
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Hallek, M. (2015) · American Journal of Hematology · doi:10.1002/ajh.23979 · Cited by 263
Guo, A., Lu, P., Coffey, G., Conley, P., Pandey, A., & Wang, Y. L. (2017) · Oncotarget · doi:10.18632/oncotarget.14588 · Cited by 52
“Besides ibrutinib, these include dasatinib [35, 36], SYK inhibitors [37-40].”
BackgroundStepanek, O., Draber, P., Drobek, A., Horejsi, V., & Brdicka, T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202401 · Cited by 31
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- MCCaig, A. M., Cosimo, E., Leach, M. T., & Michie, A. M.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2011-02-24
- Volume
- 153
- Issue
- 2
- Pages
- 199-211
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1551073524
- Cited by
- 76
- References
- 5
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08507.x
- The paper
- MCCaig, A. M., Cosimo, E., Leach, M. T., & Michie, A. M. (2011). Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro‐survival microenvironmental signals. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08507.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.